Bicycle therapeutics announces proposed $125,000,000 public offering of american depositary shares

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that it has commenced an underwritten public offering of $125,000,000 of american depositary shares (“adss”), each representing one ordinary share. all of the adss in the proposed offering will be sold by bicycle. in connection with the offering, bi
BCYC Ratings Summary
BCYC Quant Ranking